Tejaswini Kulkarni1, John Willoughby2, Maria Del Pilar Acosta Lara1, Young-Il Kim3, Rekha Ramachandran4, C Bruce Alexander5, Tracy Luckhardt2, Victor J Thannickal1, Joao A de Andrade6. 1. Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Alabama at Birmingham, 1900 University Blvd., Tinsley Harrison Tower, Suite 422, Birmingham, AL 35294, United States; Birmingham VA Medical Center, 700 South 19th Street, 6th Floor, Rm 6318, Birmingham, AL 35233, United States. 2. Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Alabama at Birmingham, 1900 University Blvd., Tinsley Harrison Tower, Suite 422, Birmingham, AL 35294, United States. 3. Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Alabama at Birmingham, 1900 University Blvd., Tinsley Harrison Tower, Suite 422, Birmingham, AL 35294, United States; Division of Preventive Medicine, Department of Medicine, University of Alabama at Birmingham, Medical Towers, Suite 621, 1720 2nd Ave South, Birmingham, AL 35294, United States; Birmingham VA Medical Center, 700 South 19th Street, 6th Floor, Rm 6318, Birmingham, AL 35233, United States. 4. Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Alabama at Birmingham, 1900 University Blvd., Tinsley Harrison Tower, Suite 422, Birmingham, AL 35294, United States; Division of Preventive Medicine, Department of Medicine, University of Alabama at Birmingham, Medical Towers, Suite 621, 1720 2nd Ave South, Birmingham, AL 35294, United States. 5. Department of Pathology, University of Alabama at Birmingham, P210 West Pavilion, 619 South 19th Street, Birmingham, AL 35233, United States. 6. Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Alabama at Birmingham, 1900 University Blvd., Tinsley Harrison Tower, Suite 422, Birmingham, AL 35294, United States; Birmingham VA Medical Center, 700 South 19th Street, 6th Floor, Rm 6318, Birmingham, AL 35233, United States. Electronic address: joao@uab.edu.
Abstract
BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease with poor prognosis and limited therapeutic options. The 2011 ATS/ERS/JRS/ALAT consensus statement provided a number of recommendations for the management of IPF patients. The primary objective of this study was to determine if "bundling" these recommendations in the management of patients with IPF impacts clinical outcomes. METHODS: We conducted a single center, retrospective cohort study of 284 patients diagnosed with IPF. The proposed bundle of care (BOC) components were: (1) visits to a specialized interstitial lung diseases clinic with evaluation of pulmonary function tests at least twice yearly; (2) referral to pulmonary rehabilitation yearly; (3) timed walk test yearly; (4) echocardiogram yearly; and (5) gastroesophageal reflux therapy. Each component of the BOC was given a score of "1" per year of follow up, and the average sum of the scores (ranging from 0 to 5) was determined for the entire period of follow-up (BOCS), as well as during the first year of follow-up (BOCY1). The primary outcome measure was transplant-free survival. RESULTS: Age, gender, smoking status, BMI, %FVC, %DLCO did not differ between levels of BOCS and BOCY1. Lowest BOCS (≤1) was associated with a lower transplant-free survival independent of age and %FVC compared to patients with the highest BOCS (>4) (HR 2.274, CI 1.12-4.64, p = 0.024). Lower BOCY1 was associated with a higher risk for transplant or death independent of age and %FVC in comparison to patients with highest BOCY1 (≤1 vs. >4, HR 2.23, p = 0.014; >1 to 2 vs. >4, HR 1.87, p = 0.011; >2 to 3 vs. >4, HR 1.72, p = 0.019). CONCLUSION: IPF patients with higher BOC scores had improved transplant-free survival. Prospective studies are needed to confirm these findings and determine the best strategies for the management of patients with IPF. Published by Elsevier Ltd.
BACKGROUND:Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease with poor prognosis and limited therapeutic options. The 2011 ATS/ERS/JRS/ALAT consensus statement provided a number of recommendations for the management of IPF patients. The primary objective of this study was to determine if "bundling" these recommendations in the management of patients with IPF impacts clinical outcomes. METHODS: We conducted a single center, retrospective cohort study of 284 patients diagnosed with IPF. The proposed bundle of care (BOC) components were: (1) visits to a specialized interstitial lung diseases clinic with evaluation of pulmonary function tests at least twice yearly; (2) referral to pulmonary rehabilitation yearly; (3) timed walk test yearly; (4) echocardiogram yearly; and (5) gastroesophageal reflux therapy. Each component of the BOC was given a score of "1" per year of follow up, and the average sum of the scores (ranging from 0 to 5) was determined for the entire period of follow-up (BOCS), as well as during the first year of follow-up (BOCY1). The primary outcome measure was transplant-free survival. RESULTS: Age, gender, smoking status, BMI, %FVC, %DLCO did not differ between levels of BOCS and BOCY1. Lowest BOCS (≤1) was associated with a lower transplant-free survival independent of age and %FVC compared to patients with the highest BOCS (>4) (HR 2.274, CI 1.12-4.64, p = 0.024). Lower BOCY1 was associated with a higher risk for transplant or death independent of age and %FVC in comparison to patients with highest BOCY1 (≤1 vs. >4, HR 2.23, p = 0.014; >1 to 2 vs. >4, HR 1.87, p = 0.011; >2 to 3 vs. >4, HR 1.72, p = 0.019). CONCLUSION: IPF patients with higher BOC scores had improved transplant-free survival. Prospective studies are needed to confirm these findings and determine the best strategies for the management of patients with IPF. Published by Elsevier Ltd.
Authors: Edward K Kasper; Gary Gerstenblith; Gail Hefter; Elizabeth Van Anden; Jeffrey A Brinker; David R Thiemann; Michael Terrin; Sandra Forman; Sheldon H Gottlieb Journal: J Am Coll Cardiol Date: 2002-02-06 Impact factor: 24.094
Authors: A Casas; T Troosters; J Garcia-Aymerich; J Roca; C Hernández; A Alonso; F del Pozo; P de Toledo; J M Antó; R Rodríguez-Roisín; M Decramer Journal: Eur Respir J Date: 2006-04-12 Impact factor: 16.671
Authors: Talmadge E King; Williamson Z Bradford; Socorro Castro-Bernardini; Elizabeth A Fagan; Ian Glaspole; Marilyn K Glassberg; Eduard Gorina; Peter M Hopkins; David Kardatzke; Lisa Lancaster; David J Lederer; Steven D Nathan; Carlos A Pereira; Steven A Sahn; Robert Sussman; Jeffrey J Swigris; Paul W Noble Journal: N Engl J Med Date: 2014-05-18 Impact factor: 91.245
Authors: Nicholas S Hopkinson; Catherine Englebretsen; Nicholas Cooley; Kevin Kennie; Mun Lim; Thomas Woodcock; Anthony A Laverty; Sandra Wilson; Sarah L Elkin; Cielito Caneja; Christine Falzon; Helen Burgess; Derek Bell; Dilys Lai Journal: Thorax Date: 2011-08-16 Impact factor: 9.139
Authors: Joao A de Andrade; Tejaswini Kulkarni; Megan L Neely; Anne S Hellkamp; Amy Hajari Case; Daniel A Culver; Kalpalatha Guntupalli; Shaun Bender; Craig S Conoscenti; Laurie D Snyder Journal: Respir Res Date: 2022-01-07
Authors: Evans R Fernández Pérez; Pearlanne Zelarney; Shirley Thomas; Deborah A Shoop; Jessica L Munson; Kelsey D Johnson; Matthew E Stern; Sarah Meadows Journal: ERJ Open Res Date: 2018-02-16